I Can See Clearly Now: Survey Results From Neonatal Staff on Mydriatic Use In Retinopathy of Prematurity Screening

Lisa Kremer1, Roland Broadbent2, David Reith2, Natalie J Medlicott1
School of Pharmacy1, and Department of Women’s and Children’s Health2, University of Otago.

Methods

• In Australia and New Zealand, ~1/3 premature infants/year are screened for ROP. ~70% of screened infants do not have ROP. ~25% of screened infants have stage 1 or 2 ROP. ~5% of screened infants have stage 3 or 4 ROP.

Aims

• To establish the variation in mydriatic regimens in Australia and New Zealand.

• To estimate the frequency of adverse drug events after mydriatic administration.

Results

• There were four different combinations of phenylephrine and tropicamide used in Australia and New Zealand NICU’s (n = 9). Those that used phenylephrine/tropicamid used either 0.5% or 1% tropicamide and always used 2.5% phenylephrine.

• The majority of nursing staff administer one (n=22) or two (n=16) standard drops for ROP eye examination.

• Those that administered a microdrop used a needleless IV cannula or microdrop needle.

Discussion

• An appropriately powered multicentre study is required to establish an effective low dose for mydriasis.

• An appropriately powered randomised controlled trial is required to determine the incidence of adverse drug effects with the variation in mydriatic regimens, especially with the growing number of extremely low birth weight infants. This study may also be able to identify if there is a subset of premature infants who are more susceptible to mydriatic induced adverse drug effects.

Conclusions

• Participants associate eye checks with significant harm, including NEC.

• There is a wide variety of mydriatic regimens in Australia and New Zealand NICU’s with a 37.5 fold unintentional difference in phenylephrine dosing.

• It is likely that unnecessarily high doses are being used and that may increase the risk for adverse effects.

• Over half of the nursing staff dilute eye drops into a lower concentration, suggesting that a new proprietary eye drop is needed.

Acknowledgments

Contributing NICU staff from around NZ and Australia.
Rewa Pene Professional Photographer. Masters Scholarship; University of Otago, Conference Scholarship; Graduate Research School.

Further information

Email: Lisa.Kremer@otago.ac.nz

Figure 1. Reported adverse effects, by nursing staff, following mydriatic eye drop administration

Figure 2. Variation of cyclopentolate concentration in nurse prepared eye drops

Figure 3. Variation of phenylephrine concentration in nurse prepared eye drops